Evidence map›Paper›PMID 31554200›Full record

ArticlePathogens (Basel, Switzerland)2019

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study.

Birkneh Tilahun Tadesse, Adugna Chala, Jackson Mukonzo, Tolosssa Eticha Chaka, Sintayehu Tadesse, Eyasu Makonnen, Zabrina L Brumme, Chanson J Brumme, Eleni Aklillu

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Birkneh Tilahun TadesseDivision of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. birknehtilahun@gmail.com.ORCID 0000-0003-4005-8605
Adugna ChalaDepartment of Pharmacology, College of Health Sciences, Addis Ababa University, Addis Ababa 9086, Ethiopia. adugnadema@gmail.com.ORCID 0000-0003-3209-2731
Jackson MukonzoDepartment of Pharmacology, College of Health Sciences, Makerere University, Kampala, Uganda. mukojack@yahoo.co.uk.
Tolosssa Eticha ChakaAdama General Hospital and Medical College, Adama 84, Ethiopia. tecb2006@gmail.com.ORCID 0000-0001-8983-2388
Sintayehu TadesseDepartment of Pharmacology, College of Health Sciences, Addis Ababa University, Addis Ababa 9086, Ethiopia. ssintayehu2010@gmail.com.
Eyasu MakonnenDepartment of Pharmacology, College of Health Sciences, Addis Ababa University, Addis Ababa 9086, Ethiopia. eyasumakonnen@yahoo.com.ORCID 0000-0002-9259-5288
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada. zbrumme@cfenet.ubc.ca.ORCID 0000-0002-8157-1037
Chanson J BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada. cbrumme@cfenet.ubc.ca.
Eleni AklilluDivision of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. eleni.aklillu@ki.se.ORCID 0000-0002-9788-0790

Funding

CIHR PJT-148621Vetenskapsrådet 2015-03295
6 · The paper itself

Abstract

There is limited data on virologic outcome and its correlates among HIV-infected children in resource-limited settings. We investigated rate and correlates of virologic outcome among treatment naïve HIV-infected Ethiopian children initiating cART, and were followed prospectively at baseline, 8, 12, 24 and 48 weeks using plasma viral load, clinical examination, laboratory tests and pretreatment HIV drug resistance (PDR) screening. Virologic outcome was assessed using two endpoints-virological suppression defined as having "undetectable" plasma viral load < 150 RNA copies/mL, and rebound defined as viral load ≥150 copies/mL after achieving suppression. Cox Proportional Hazards Regression was employed to assess correlates of outcome. At the end of follow up, virologic outcome was measured for 110 participants. Overall, 94(85.5%) achieved virological suppression, of which 36(38.3%) experienced virologic rebound. At 48 weeks, 9(8.2%) children developed WHO-defined virological treatment failure. Taking tenofovir-containing regimen (Hazard Ratio (HR) 3.1-[95% confidence interval (95%CI) 1.0-9.6],

Indexed as

cART naïveHIVpretreatment HIV drug resistancevirologic outcome

Identifiers

PMID31554200
PMCPMC6963769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.